Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are gaining popularity in Central Asia due to the rising prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The demand for these drugs is increasing as more people are being diagnosed with these conditions, leading to a surge in the market for bronchodilator drugs in the region.
Customer preferences: Patients in Central Asia are increasingly preferring bronchodilator drugs due to their effectiveness in relieving respiratory distress. These drugs work by relaxing the muscles in the airways, making it easier to breathe. Patients prefer these drugs over other forms of medication as they provide quick relief from symptoms such as coughing, wheezing, and shortness of breath.
Trends in the market: The market for bronchodilator drugs is witnessing significant growth in Central Asia due to the increasing prevalence of respiratory diseases in the region. The demand for these drugs is also being driven by the growing awareness among patients about the benefits of early diagnosis and treatment of respiratory diseases. Moreover, the availability of generic versions of these drugs is making them more affordable and accessible to patients in the region.
Local special circumstances: Central Asia is a region that is prone to dust storms and air pollution, which can exacerbate respiratory conditions. This has led to an increase in the number of people suffering from respiratory diseases in the region. Additionally, the lack of access to quality healthcare in some parts of Central Asia is also contributing to the rise in respiratory diseases. As a result, the demand for bronchodilator drugs is expected to continue to grow in the region.
Underlying macroeconomic factors: The economic growth in Central Asia is also contributing to the growth of the bronchodilator drugs market in the region. As the standard of living improves, people are becoming more aware of their health and are willing to spend more on healthcare. This is leading to an increase in demand for high-quality medication, including bronchodilator drugs. Additionally, the growing healthcare infrastructure in the region is also contributing to the growth of the market. The increasing number of hospitals and clinics in Central Asia is making it easier for people to access healthcare services, including medication for respiratory diseases.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
